POON CHRISTINE A — SEC insider filings
SEC reporting owner CIK 1189014. 75 insider filings on record with FilingPulse; latest filed 2026-11-04.
Transaction summary — filings shown
Covers the 50 most recent of 75 filings on record, filed 2022-08-11 to 2026-11-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 26 legs across 5 filings — 52,448 shares, $44,021,415 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 111.
- Largest priced transaction: sale of 5,352 shares @ $1,159.56 ($6,205,965) in REGENERON PHARMACEUTICALS, INC., filed 2024-08-19.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC. (REGN) | Director | 9 | — | 26 legs · 52,448 sh · $44,021,415 | 21 |
| PRUDENTIAL FINANCIAL INC (PRU) | Director | 22 | — | — | 67 |
| SHERWIN WILLIAMS CO (SHW) | Director | 14 | — | — | 14 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | Director | 5 | — | — | 9 |
Insider filings — POON CHRISTINE A
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-04 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 7,830 @ $376.69 · Sale (S): 218 @ $966.74 · Sale (S): 772 @ $967.38 · Sale (S): 2,499 @ $968.58 · Sale (S): 3,203 @ $969.50 · Sale (S): 937 @ $970.51 · +2 more | EDGAR |
| 2026-09-14 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 161 (derivative) @ $118.48 · Grant/award (A): 49 (derivative) @ $118.48 · Grant/award (A): 21 (derivative) @ $118.48 | EDGAR |
| 2026-06-15 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 177 (derivative) @ $106.51 · Grant/award (A): 54 (derivative) @ $106.51 · Grant/award (A): 23 (derivative) @ $106.51 | EDGAR |
| 2026-05-29 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 2,567 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 3,318 @ $0 · Option exercise (M): 3,318 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Option exercise (M): 1,765 @ $0 · Disposition to issuer (D): 1,765 @ $102.58 · Grant/award (A): 1,754 (derivative) @ $0 · Option exercise (M): 1,765 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 201 (derivative) @ $92.34 · Grant/award (A): 61 (derivative) @ $92.34 · Grant/award (A): 26 (derivative) @ $92.34 | EDGAR |
| 2026-01-06 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 151 (derivative) @ $117.05 · Grant/award (A): 46 (derivative) @ $117.05 · Grant/award (A): 19 (derivative) @ $117.05 | EDGAR |
| 2025-10-31 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 6,500 @ $520.01 · Sale (S): 650 @ $652.68 · Sale (S): 2,735 @ $653.50 · Sale (S): 1,915 @ $654.42 · Sale (S): 100 @ $655.10 · Sale (S): 712 @ $656.50 · +4 more | EDGAR |
| 2025-09-12 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 163 (derivative) @ $106.99 · Grant/award (A): 50 (derivative) @ $106.99 · Grant/award (A): 21 (derivative) @ $106.99 | EDGAR |
| 2025-06-16 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 164 (derivative) @ $104.90 · Grant/award (A): 50 (derivative) @ $104.90 · Grant/award (A): 21 (derivative) @ $104.90 | EDGAR |
| 2025-05-22 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 1,435 @ $0 · Grant/award (A): 3,318 (derivative) @ $0 · Option exercise (M): 1,435 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Option exercise (M): 1,321 @ $0 · Disposition to issuer (D): 1,321 @ $107.40 · Grant/award (A): 1,675 (derivative) @ $0 · Option exercise (M): 1,321 (derivative) @ $0 | EDGAR |
| 2025-04-07 | 4 | SHERWIN WILLIAMS CO (SHW) | Grant/award (A): 4.11 @ $338.25 | EDGAR |
| 2025-03-17 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 162 (derivative) @ $105.04 · Grant/award (A): 49 (derivative) @ $105.04 · Grant/award (A): 16 (derivative) @ $105.04 | EDGAR |
| 2025-02-20 | 4 | SHERWIN WILLIAMS CO (SHW) | Grant/award (A): 517 @ $0 | EDGAR |
| 2025-01-07 | 4 | SHERWIN WILLIAMS CO (SHW) | Grant/award (A): 25.19 @ $335 | EDGAR |
| 2025-01-06 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Code (W): 14 @ $0 · Grant/award (A): 166 @ $0 · Grant/award (A): 1,958 (derivative) @ $0 | EDGAR |
| 2024-12-16 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 134 (derivative) @ $120.61 · Grant/award (A): 41 (derivative) @ $120.61 · Grant/award (A): 13 (derivative) @ $120.61 | EDGAR |
| 2024-10-08 | 4 | SHERWIN WILLIAMS CO (SHW) | Grant/award (A): 22.65 @ $372.47 | EDGAR |
| 2024-09-16 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 138 (derivative) @ $115.84 · Grant/award (A): 42 (derivative) @ $115.84 · Grant/award (A): 14 (derivative) @ $115.84 | EDGAR |
| 2024-08-19 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 10,838 @ $413.33 · Sale (S): 1,012 @ $1,155.72 · Sale (S): 2,368 @ $1,156.30 · Sale (S): 1,560 @ $1,157.33 · Sale (S): 212 @ $1,158.02 · Sale (S): 5,352 @ $1,159.56 · +3 more | EDGAR |
| 2024-07-09 | 4 | SHERWIN WILLIAMS CO (SHW) | Grant/award (A): 28.55 @ $295.50 | EDGAR |
| 2024-06-17 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 139 (derivative) @ $113.97 · Grant/award (A): 42 (derivative) @ $113.97 · Grant/award (A): 14 (derivative) @ $113.97 | EDGAR |
| 2024-05-23 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 1,435 (derivative) @ $0 · Grant/award (A): 2,982 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 1,261 (derivative) @ $0 | EDGAR |
| 2024-05-13 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Option exercise (M): 1,935 @ $0 · Disposition to issuer (D): 1,935 @ $117.95 · Option exercise (M): 1,935 (derivative) @ $0 | EDGAR |
| 2024-04-09 | 4 | SHERWIN WILLIAMS CO (SHW) | Grant/award (A): 25.45 @ $331.56 | EDGAR |
| 2024-03-18 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 140 (derivative) @ $111.74 · Grant/award (A): 43 (derivative) @ $111.74 · Grant/award (A): 22 (derivative) @ $111.74 | EDGAR |
| 2024-02-15 | 4 | SHERWIN WILLIAMS CO (SHW) | Grant/award (A): 594 @ $0 | EDGAR |
| 2024-01-09 | 4 | SHERWIN WILLIAMS CO (SHW) | Grant/award (A): 28.41 @ $296.96 | EDGAR |
| 2024-01-04 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 135 @ $0 · Grant/award (A): 1,607 (derivative) @ $0 | EDGAR |
| 2023-12-18 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 142 (derivative) @ $105.21 · Grant/award (A): 43 (derivative) @ $105.21 · Grant/award (A): 22 (derivative) @ $105.21 | EDGAR |
| 2023-10-10 | 4 | SHERWIN WILLIAMS CO (SHW) | Grant/award (A): 32.10 @ $253.15 | EDGAR |
| 2023-09-18 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 148 (derivative) @ $99.14 · Grant/award (A): 45 (derivative) @ $99.14 · Grant/award (A): 23 (derivative) @ $99.14 | EDGAR |
| 2023-08-25 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 12,280 @ $273.67 · Sale (S): 300 @ $837.92 · Sale (S): 1,998 @ $838.60 · Sale (S): 3,032 @ $839.45 · Sale (S): 6,450 @ $840.65 · Sale (S): 500 @ $841.05 · +1 more | EDGAR |
| 2023-07-13 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 16,375 (derivative) @ $0 | EDGAR |
| 2023-07-10 | 4 | SHERWIN WILLIAMS CO (SHW) | Grant/award (A): 31.62 @ $257 | EDGAR |
| 2023-06-20 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 167 (derivative) @ $86.76 · Grant/award (A): 51 (derivative) @ $86.76 · Grant/award (A): 26 (derivative) @ $86.76 | EDGAR |
| 2023-05-11 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Option exercise (M): 1,517 @ $0 · Disposition to issuer (D): 1,517 @ $81.50 · Option exercise (M): 1,517 (derivative) @ $0 · Grant/award (A): 1,840 (derivative) @ $0 | EDGAR |
| 2023-04-12 | 4 | SHERWIN WILLIAMS CO (SHW) | Grant/award (A): 36.32 @ $223.68 | EDGAR |
| 2023-03-20 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 174 (derivative) @ $82.19 · Grant/award (A): 53 (derivative) @ $82.19 · Grant/award (A): 22 (derivative) @ $82.19 | EDGAR |
| 2023-02-16 | 4 | SHERWIN WILLIAMS CO (SHW) | Grant/award (A): 711 @ $0 | EDGAR |
| 2023-01-10 | 4 | SHERWIN WILLIAMS CO (SHW) | Grant/award (A): 34.92 @ $232.66 | EDGAR |
| 2023-01-05 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 165 @ $0 · Grant/award (A): 1,929 (derivative) @ $0 | EDGAR |
| 2022-12-19 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 136 (derivative) @ $99.75 · Grant/award (A): 41 (derivative) @ $99.75 · Grant/award (A): 17 (derivative) @ $99.75 | EDGAR |
| 2022-10-11 | 4 | SHERWIN WILLIAMS CO (SHW) | Grant/award (A): 38.80 @ $209.43 | EDGAR |
| 2022-09-19 | 4 | PRUDENTIAL FINANCIAL INC (PRU) | Grant/award (A): 145 (derivative) @ $92.54 · Grant/award (A): 44 (derivative) @ $92.54 · Grant/award (A): 18 (derivative) @ $92.54 | EDGAR |
| 2022-08-11 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 15,000 @ $177.82 · Sale (S): 6,814 @ $620.47 · Sale (S): 8,186 @ $621.27 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-26 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1189014 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs